Sanofi Healthcare India Pvt. Ltd. has taken a significant step forward in treating atopic dermatitis, a chronic inflammatory skin disease, with the approval of Dupixent® (dupilumab) for adults with moderate-to-severe atopic dermatitis. The drug offers hope to those whose disease hasn’t been adequately controlled with topical therapies or for whom such therapies aren’t advisable.
Unlike existing therapies that suppress the immune system globally, Dupixent® zeroes in on the type 2 inflammation that underlies the disease. This targeted approach to treatment has transformed the therapeutic landscape for atopic dermatitis globally. Approved in numerous countries, including the U.S., the European Union, Japan, and more than 60 others, Dupixent® has brought significant relief from disease symptoms and improved quality of life for those suffering from this challenging skin condition.
Atopic dermatitis is characterized by intense itching, skin dryness, redness, and oozing. Its chronic nature, combined with visible skin lesions, often leads to considerable social stigma. It’s estimated that between 2% to 8% of adults in India suffer from the condition, and the approval of Dupixent® marks a major milestone in providing new treatment options for this underserved patient population.
Jointly developed by Sanofi and Regeneron under a global collaboration agreement, Dupixent® has already served over 600,000 patients globally and is now poised to become a vital tool in treating moderate-to-severe atopic dermatitis in India.